180 related articles for article (PubMed ID: 21046929)
1. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients.
Portenoy RK; Raffaeli W; Torres LM; Sitte T; Deka AC; Herrera IG; Wallace MS;
J Opioid Manag; 2010; 6(5):319-28. PubMed ID: 21046929
[TBL] [Abstract][Full Text] [Related]
2. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
Radbruch L; Torres LM; Ellershaw JE; Gatti A; Luis Lerzo G; Revnic J; Taylor D
Support Care Cancer; 2012 Mar; 20(3):565-73. PubMed ID: 21424794
[TBL] [Abstract][Full Text] [Related]
3. A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
Taylor D; Radbruch L; Revnic J; Torres LM; Ellershaw JE; Perelman M
J Pain Symptom Manage; 2014 Jun; 47(6):1001-7. PubMed ID: 24128821
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
Portenoy RK; Burton AW; Gabrail N; Taylor D;
Pain; 2010 Dec; 151(3):617-624. PubMed ID: 20800358
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl pectin nasal spray in breakthrough cancer pain.
Taylor D; Galan V; Weinstein SM; Reyes E; Pupo-Araya AR; Rauck R;
J Support Oncol; 2010; 8(4):184-90. PubMed ID: 20822038
[TBL] [Abstract][Full Text] [Related]
7. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
[TBL] [Abstract][Full Text] [Related]
8. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain.
Ueberall MA; Lorenzl S; Lux EA; Voltz R; Perelman M
J Pain Res; 2016; 9():571-85. PubMed ID: 27574463
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
12. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures.
Pardo J; Mena A; Jiménez E; Aymar N; Ortiz I; Roncero R; Mestre F; Vidal M
Clin Transl Oncol; 2019 Nov; 21(11):1568-1572. PubMed ID: 31093890
[TBL] [Abstract][Full Text] [Related]
15. Facilitation of accurate and effective radiation therapy using fentanyl pectin nasal spray (FPNS) to reduce incidental breakthrough pain due to procedure positioning.
Prieto I; Pardo J; Luna J; Marin JP; Olivera J; Garcia AJ; Perez AM
Scand J Pain; 2016 Apr; 11():52-58. PubMed ID: 28850470
[TBL] [Abstract][Full Text] [Related]
16. Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study.
Chen C; Bujanover S; Gupta A
J Opioid Manag; 2015; 11(2):139-46. PubMed ID: 25901479
[TBL] [Abstract][Full Text] [Related]
17. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray.
Perelman M; Knight A
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):942-7. PubMed ID: 24120713
[TBL] [Abstract][Full Text] [Related]
19. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M
J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555
[TBL] [Abstract][Full Text] [Related]
20. Fentanyl pectin nasal spray for breakthrough cancer pain.
Taylor DR; Gabrail N
Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
